145 related articles for article (PubMed ID: 12749274)
1. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.
Kurtz JE; Négrier S; Husseini F; Limacher JM; Borel C; Wagner JP; Prévot G; Bergerat JP; Dufour P
Hepatogastroenterology; 2003; 50(50):567-70. PubMed ID: 12749274
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
4. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study.
Koukourakis MI; Bizakis JG; Skoulakis CE; Kyrmizakis D; Giatromanolaki A; Papadakis CE; Prokopakis E; Amanakis Z; Hellidonis ES
Anticancer Res; 1999; 19(3B):2305-9. PubMed ID: 10472349
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.
Burtness B; Thomas L; Sipples R; McGurk M; Salikooti S; Christoforou M; Mirto G; Salem R; Sosa J; Kloss R; Rahman Z; Chung G; Lacy J; Murren JR
Cancer J; 2007; 13(4):257-62. PubMed ID: 17762761
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Jatoi A; Tirona MT; Cha SS; Alberts SR; Rowland KM; Morton RF; Nair S; Kardinal CG; Stella PJ; Mailliard JA; Sargen D; Goldberg RM
Int J Gastrointest Cancer; 2002; 32(2-3):115-23. PubMed ID: 12794247
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
Adjei AA; Argiris A; Murren JR
Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
[TBL] [Abstract][Full Text] [Related]
8. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Cascinu S; Gasparini G; Catalano V; Silva RR; Pancera G; Morabito A; Giordani P; Gattuso D; Catalano G
Ann Oncol; 1999 Nov; 10(11):1377-9. PubMed ID: 10631469
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
[TBL] [Abstract][Full Text] [Related]
10. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
Cancer Invest; 2008 Feb; 26(1):47-52. PubMed ID: 18181045
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
Stathopoulos GP; Tsavdaridis D; Malamos NA; Rigatos SK; Kosmas Ch; Pergantas N; Stathopoulos JG; Xynotroulas J
Cancer Chemother Pharmacol; 2005 Nov; 56(5):487-91. PubMed ID: 15868147
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
Knuuttila A; Ollikainen T; Halme M; Mali P; Kivisaari L; Linnainmaa K; Jekunen A; Mattson K
Anticancer Drugs; 2000 Apr; 11(4):257-61. PubMed ID: 10898540
[TBL] [Abstract][Full Text] [Related]
14. A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer.
Syrigos KN; Michalaki B; Alevyzaki F; Machairas A; Mandrekas D; Kindilidis K; Karatzas G
Anticancer Res; 2002; 22(6B):3583-8. PubMed ID: 12552960
[TBL] [Abstract][Full Text] [Related]
15. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Neri B; Cipriani G; Grifoni R; Molinara E; Pantaleo P; Rangan S; Vannini A; Tonelli P; Valeri A; Pantalone D; Taddei A; Bechi P
Oncol Res; 2009; 17(11-12):559-64. PubMed ID: 19806786
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study.
Burtness B; Powell M; Catalano P; Berlin J; Liles DK; Chapman AE; Mitchell E; Benson AB
Am J Clin Oncol; 2016 Aug; 39(4):340-5. PubMed ID: 24685886
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study.
Androulakis N; Kourousis C; Dimopoulos MA; Samelis G; Kakolyris S; Tsavaris N; Genatas K; Aravantinos G; Papadimitriou C; Karabekios S; Stathopoulos GP; Georgoulias V
J Clin Oncol; 1999 Jun; 17(6):1779-85. PubMed ID: 10561215
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
Polyzos A; Kosmas C; Toufexi H; Malamos N; Lagadas A; Kosmidis C; Ginopoulos P; Ziras N; Kandilis K; Georgoulias V
Anticancer Res; 2005; 25(5):3559-64. PubMed ID: 16101180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
